Details

Autor(en) / Beteiligte

• Jacobson, Ira M
• Gordon, Stuart C
• Kowdley, Kris V
• Yoshida, Eric M
• Rodriguez-Torres, Maribel
• Sulkowski, Mark S
• Shiffman, Mitchell L
• Lawitz, Eric
• Everson, Gregory
• Bennett, Michael
• Schiff, Eugene
• Al-Assi, M. Tarek
• Subramanian, G. Mani
• An, Di
• Lin, Ming
• McNally, John
• Brainard, Diana
• Symonds, William T
• McHutchison, John G
• Patel, Keyur
• Feld, Jordan
• Pianko, Stephen
• Nelson, David R

Titel

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

Ist Teil von

• The New England journal of medicine, 2013-05, Vol.368 (20), p.1867-1877

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2013

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In two randomized trials, the oral nucleotide polymerase inhibitor sofosbuvir combined with ribavirin for 12 or 16 weeks was effective in patients with chronic HCV genotype 2 or 3 infection for whom interferon therapy either was not an option or had failed. When studied in clinical trials, the current standard-of-care therapy for patients with hepatitis C virus (HCV) genotype 2 or 3 infection — pegylated interferon in combination with ribavirin for 24 weeks — resulted in a sustained virologic response in 70 to 85% of patients who had not received prior treatment and in 55 to 60% of those who had received treatment. 1 – 4 However, a substantial proportion of patients with HCV infection remain untreated owing to absolute or relative contraindications to interferon therapy, such as hepatic decompensation, autoimmune disease, and psychiatric illness. 5 In addition, interferon causes a range of constitutional symptoms . . .